Latest On GlycoMimetics, Inc (GLYC):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-30 15:17 EST | News | GlycoMimetics: Insider Buying Continues, And Chart Looks Healthy | N/A |  |
| 2023-05-10 16:14 EST | News | GlycoMimetics: An Asymmetric Opportunity That Could Change Hematology | N/A | |
| 2023-05-04 00:06 EST | News | GlycoMimetics, Inc. (GLYC) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-03 10:57 EST | News | GlycoMimetics GAAP EPS of -$0.17 in-line | N/A | |
| 2023-04-04 15:04 EST | News | GlycoMimetics Has Few Risks, Great Outlook In Leukemia | N/A | |
About GlycoMimetics, Inc (GLYC):
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359 to target E-selectin and a chemokine receptors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company read more...has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.
General
- Name GlycoMimetics, Inc
- Symbol GLYC
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 54
- Fiscal Year EndDecember
- IPO Date2014-01-10
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://glycomimetics.com
Valuation
- Price/Sales (Trailing 12 Mt.) 15.03
- Price/Book (Most Recent Quarter) 1.34
- Enterprise Value Revenue 3.72
- Enterprise Value EBITDA 0.09
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.28
- Next Year EPS Estimate -$1.40
- Next Quarter EPS Estimate -$0.33
- Operating Margin -507%
- Return on Assets -21%
- Return on Equity -36%
- Revenue 10.16 million
- Earnings Per Share -$1.28
- Revenue Per Share $0.22
- Gross Profit 10.16 million
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 177.14 million
- EBITDA -59150020
- Analyst Target Price $10.25
- Book Value Per Share $2.62
Share Statistics
- Shares Outstanding 51.49 million
- Shares Float 31.78 million
- % Held by Insiders 215%
- % Held by Institutions 78.59%
- Shares Short 1.07 million
- Shares Short Prior Month 919111
- Short Ratio 1.15
- Short % of Float 4%
- Short % of Shares Outstanding 2%
Technicals
- Beta 2.4
- 52 Week High $5.19
- 52 Week Low $1.94
- 50 Day Moving Average 3.61
- 200 Day Moving Average 3.56
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
GlycoMimetics, Inc (GLYC) Dividend Calendar:
GlycoMimetics, Inc (GLYC) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
GlycoMimetics, Inc (GLYC) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 11.72 million | 10.67 million | N/A | N/A | 11.47 million |
| Income Before Tax | -15.56 million | -13.72 million | N/A | N/A | -14.73 million |
| Selling General Administrative | 4.01 million | 4.06 million | N/A | N/A | 3.87 million |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | -15.57 million | -13.73 million | N/A | N/A | -15.34 million |
| Operating Income | -15.57 million | -13.73 million | N/A | N/A | -15.34 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | 163000 | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 608792 |
| Net Income From Continuing Operations | -15.56 million | -13.72 million | N/A | N/A | -14.73 million |
| Net Income Applicable to Common Shares | -15.56 million | -13.72 million | -14.08 million | -7.66 million | -14.73 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | 89000 | -1.77 million | 1.7 million | 28112 | -1.62 million |
| Total Cash Flow from Investing Activities | -15813 | -6383 | -8136 | -12357 | -18266 |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | 4.55 million | N/A | N/A | 119822 | 186770 |
| Change to Operating Activities | N/A | -700824 | 409242 | -49028 | -391408 |
| Change in Cash | -6.97 million | N/A | N/A | -12.69 million | -13.28 million |
| Total Cash from Operating Activities | -11.5 million | -14.55 million | -3.5 million | -12.79 million | -13.45 million |
| Depreciation | 66527 | N/A | N/A | 67843 | -233083 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 1.69 million | 1.76 million | 1.82 million | 1.89 million | 2.05 million |
| Capital Expenditures | 15813 | N/A | N/A | 12357 | 18266 |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 14.61 million | 12.15 million | N/A | N/A | 13.77 million |
| Total Stockholder Equity | 128.22 million | 138.27 million | N/A | N/A | 154.2 million |
| Other Current Liabilities | 898549 | 874158 | N/A | N/A | N/A |
| Total Assets | 142.83 million | 150.42 million | N/A | N/A | 167.97 million |
| Common Stock | 49018 | 47829 | N/A | 43581 | 43465 |
| Other Current Assets | 1.24 million | 2.77 million | N/A | N/A | N/A |
| Retained Earnings | -309.47 million | -293.91 million | N/A | -266.11 million | -258.44 million |
| Other Liabilities | 264329 | N/A | N/A | 393273 | N/A |
| Other Assets | 1.61 million | N/A | N/A | 1.61 million | 1.61 million |
| Cash | 137.04 million | 142.87 million | N/A | N/A | 158.2 million |
| Total Current Liabilities | 12.43 million | 9.82 million | N/A | N/A | 10.95 million |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 620673 | 661541 | N/A | 3.6 million | 3.83 million |
| Total Current Assets | 138.27 million | 145.64 million | N/A | N/A | 162.53 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 128.22 million | 138.27 million | 148.49 million | 148.49 million | 154.2 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 11.53 million | 8.94 million | N/A | N/A | 1.44 million |
GlycoMimetics, Inc (GLYC) Chart:
GlycoMimetics, Inc (GLYC) News:
Below you will find a list of latest news for GlycoMimetics, Inc (GLYC) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
GlycoMimetics, Inc (GLYC) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest GLYC Trades:
GlycoMimetics, Inc (GLYC) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-06 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-06 | 8-K (Current report) | |
| 2020-11-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-07 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-10-07 | 8-K (Current report) | |
| 2020-07-31 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-31 | 8-K (Current report) | |
| 2020-07-20 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-07-10 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-05-27 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-27 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-27 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-27 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-27 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-27 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-27 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-26 | 8-K (Current report) | |
| 2020-05-08 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-05-01 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
GlycoMimetics, Inc (GLYC) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of GlycoMimetics, Inc (GLYC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 215%
Institutional Ownership: 7859%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-11-04 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 506,155.00 | 2.60 | 1,316,003.00 | 3,712,350.00 | |
| 2020-11-04 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 674,492.00 | 2.60 | 1,753,679.20 | 4,980,812.00 | |
| 2020-11-04 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 86,090.00 | 2.60 | 223,834.00 | 630,453.00 | |
| 2020-10-30 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 250,755.00 | 2.75 | 689,576.25 | 3,206,195.00 | |
| 2020-10-30 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 666,385.00 | 2.75 | 1,832,558.75 | 4,306,320.00 | |
| 2020-10-30 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 15,472.00 | 2.75 | 42,548.00 | 544,363.00 | |
| 2020-03-09 | DANIEL M JUNIUS | Director | Buy | 20,000.00 | 3.40 | 68,000.00 | 38,000.00 | |
| 2020-01-06 | John L. Magnani | SVP of Research, CSO | Buy | 106,983.00 | 1.12 | 119,820.96 | 289,760.00 | |
| 2019-12-20 | John L. Magnani | SVP of Research, CSO | Buy | 106,984.00 | 1.12 | 119,822.08 | 182,777.00 | |
| 2019-09-05 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 689,834.00 | 3.18 | 2,195,051.79 | 2,955,440.00 | |
| 2019-09-05 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 853,956.00 | 3.18 | 2,717,287.99 | 3,639,935.00 | |
| 2019-09-05 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 124,956.00 | 3.18 | 397,609.99 | 528,891.00 | |
| 2019-08-13 | DANIEL M JUNIUS | Director | Buy | 10,000.00 | 3.18 | 31,800.00 | 18,000.00 | |
| 2019-08-06 | Rachel K. King | President, CEO | Buy | 166,759.00 | 1.12 | 186,770.08 | 307,144.00 | |
| 2018-10-18 | John L. Magnani | SVP of Research, CSO | Sell | 3,527.00 | 14.02 | 49,448.54 | 75,793.00 | |
| 2018-10-17 | John L. Magnani | SVP of Research, CSO | Sell | 7,273.00 | 14.00 | 101,822.00 | 79,320.00 | |
| 2018-10-16 | John L. Magnani | SVP of Research, CSO | Sell | 14,200.00 | 14.01 | 198,942.00 | 86,593.00 | |
| 2018-06-11 | Brian M. Hahn | CFO | Sell | 19,345.00 | 18.04 | 348,983.80 | 0.00 | |
| 2018-06-11 | Brian M. Hahn | CFO | Buy | 5,260.00 | 1.12 | 5,891.20 | 19,345.00 | |
| 2018-05-23 | John L. Magnani | SVP of Research, CSO | Buy | 1,491.00 | 0.33 | 492.03 | 100,793.00 | |